Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Brianna St. Cyr"'
Autor:
Diana Jaeger, Ranit Aharonov, Yael Spector, Brianna St. Cyr, Ayelet Chajut, Wolf Mueller, Tina Bocker Edmonston, Ulrike Lass, Shai Rosenwald
Publikováno v:
The Oncologist. 16:165-174
Background. Identification of the tissue of origin of a brain metastatic tumor is vital to its management. Carcinoma of unknown primary (CUP) is common in oncology, representing 3%–5% of all invasive malignancies. We aimed to validate a recently de
Autor:
Nir Dromi, Ranit Aharonov, Iris Barshack, Sima Benjamin, Irit Krivitsky, Ilanit Burnstein, Laurie Horowitz, Yajue Huang, Craig Thurm, J. Steve Hou, Michal Kushnir, Marluce Bibbo, Shlomit Gilad, Meora Feinmesser, Gila Lithwick-Yanai, Brianna St. Cyr, Hadas Gibori, Mats Sanden, Tina Bocker Edmonston
Publikováno v:
The Journal of molecular diagnostics : JMD. 14(5)
For patients with primary lung cancer, accurate determination of the tumor type significantly influences treatment decisions. However, techniques and methods for lung cancer typing lack standardization. In particular, owing to limited tumor sample am
Autor:
Noga Yerushalmi, Eddie Fridman, Brianna St. Cyr, Sofia Zilber, Iris Barshack, Mats Sanden, Robert Wassman, Yael Spector, Yajue Huang, Hila Benjamin
Publikováno v:
Cancer Research. 73:802-802
Background: Renal cancers account for more than 3% of adult malignancies and result in more than 13,000 deaths per year in the US alone. The four most common types of kidney tumors include the malignant renal cell carcinomas: clear cell, papillary an
Autor:
George Pentheroudakis, Vassiliki Malamou-Mitsi, Hila Benjamin, George Fountzilas, Dimitrios Krikelis, Brianna St. Cyr, Yael Spector, Anna Gousia, Mats Sanden, Eti Meiri, Aikaterini Stoyianni, Karin Ashkenazi, Vassiliki Kotoula, Nicholas Pavlidis
Publikováno v:
Journal of Clinical Oncology. 30:10575-10575
10575 Background: Identification of the tissue of origin of metastatic tumors is important for estimation of prognosis and patient management. Carcinoma of unknown primary (CUP) is not uncommon in oncology, representing 3-5% of all newly found malign